MCID: RCT021
MIFTS: 53

Rectum Cancer

Categories: Cancer diseases, Gastrointestinal diseases

Aliases & Classifications for Rectum Cancer

MalaCards integrated aliases for Rectum Cancer:

Name: Rectum Cancer 12 15 17
Malignant Neoplasm of Rectum 12 32
Rectal Cancer 12 54
Malignant Tumor of Rectum 12
Carcinoma of the Rectum 12
Malignant Rectal Tumor 12
Malignant Rectum Tumor 12
Carcinoma of Rectum 12
Cancer of Rectum 12
Rectal Carcinoma 54
Rectal Neoplasms 43
Rectal Cancers 15
Cancer, Rectal 39

Classifications:



External Ids:

Disease Ontology 12 DOID:1993
ICD9CM 34 154.1
MeSH 43 D012004
NCIt 49 C7418 C9382
SNOMED-CT 67 93984006
ICD10 32 C20
UMLS 71 C0007113 C0949022

Summaries for Rectum Cancer

Disease Ontology : 12 A colorectal cancer that is located in the rectum.

MalaCards based summary : Rectum Cancer, also known as malignant neoplasm of rectum, is related to lynch syndrome and rectum adenocarcinoma. An important gene associated with Rectum Cancer is CEACAM5 (CEA Cell Adhesion Molecule 5), and among its related pathways/superpathways are Endometrial cancer and Pathways in cancer. The drugs Guaifenesin and Iron have been mentioned in the context of this disorder. Affiliated tissues include rectum, colon and lymph node, and related phenotype is neoplasm.

Related Diseases for Rectum Cancer

Diseases in the Rectum Cancer family:

Rectum Carcinoma in Situ

Diseases related to Rectum Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 795)
# Related Disease Score Top Affiliating Genes
1 lynch syndrome 33.0 MUTYH MSH2 MLH1 MIR17 KRAS APC
2 rectum adenocarcinoma 32.9 MSH2 MLH1 MIR143 KRT20 KRAS CEACAM5
3 rectosigmoid junction neoplasm 32.8 CEACAM5 APOLD1
4 colon adenocarcinoma 32.7 TYMS MLH1 MIR21 KRT20 KRAS CEACAM7
5 colorectal cancer 31.5 TYMS TYMP MUTYH MSH2 MMP7 MLH1
6 familial adenomatous polyposis 31.5 MUTYH MSH2 MLH1 KRAS APC
7 anal fistula 31.4 MSH2 MLH1 APOLD1
8 appendix adenocarcinoma 31.2 KRT20 KRAS CEACAM5
9 adenosquamous carcinoma 31.2 KRAS CEACAM7 CEACAM5
10 mucinous adenocarcinoma 31.1 MLH1 KRT20 KRAS CEACAM5
11 linitis plastica 31.1 KRT20 CEACAM5 APOLD1
12 anal squamous cell carcinoma 31.0 MLH1 APOLD1 APC
13 signet ring cell adenocarcinoma 31.0 MSH2 MLH1 KRT20 KRAS CEACAM5
14 papilloma 31.0 TYMS KRT20 KRAS CDKN1A
15 anus cancer 31.0 KRAS CEACAM5 APOLD1
16 dihydropyrimidine dehydrogenase deficiency 30.9 TYMS TYMP DPYD
17 adenoma 30.8 MUTYH MSH2 MLH1 KRAS APC
18 pseudomyxoma peritonei 30.8 KRT20 KRAS CEACAM5
19 cholangiocarcinoma 30.8 MMP7 MIR21 KRT20 KRAS CEACAM5 APC
20 transverse colon cancer 30.7 MLH1 KRT20 KRAS CEACAM5
21 intrahepatic cholangiocarcinoma 30.7 KRT20 KRAS APC
22 tubular adenocarcinoma 30.7 MIR21 KRT20 CEACAM5
23 papillary adenocarcinoma 30.7 MIR21 KRAS CEACAM5
24 rectosigmoid cancer 30.7 MUTYH KRAS CEACAM5 APOLD1
25 krukenberg carcinoma 30.7 KRT20 CEACAM5
26 gastrointestinal carcinoma 30.6 TYMS KRT20 DPYD CEACAM7 CEACAM5
27 endometriosis 30.6 MMP7 MIR20A MIR145 MIR143
28 intestinal obstruction 30.6 KRT20 CEACAM5 APOLD1
29 transitional cell carcinoma 30.6 MSH2 MLH1 KRT20 CDKN1A
30 adenocarcinoma in situ 30.6 KRT20 KRAS CEACAM5
31 attenuated familial adenomatous polyposis 30.5 MUTYH MSH2 APC
32 polyposis syndrome, hereditary mixed, 1 30.5 MUTYH MLH1 APC
33 colorectal adenoma 30.5 MUTYH MSH2 MMP7 MLH1 MIR17 KRAS
34 mismatch repair cancer syndrome 30.5 MSH2 MLH1 APC
35 large cell carcinoma 30.5 KRT20 KRAS CEACAM5
36 lymphoma, non-hodgkin, familial 30.5 MSH2 MIR21 MIR20A MIR17 APC
37 familial colorectal cancer 30.5 MUTYH MSH2 MLH1 APC
38 cervical squamous cell carcinoma 30.4 TYMP MLH1 MIR143 KRAS
39 villous adenoma 30.4 MLH1 KRT20 KRAS CEACAM5 APOLD1 APC
40 small cell cancer of the lung 30.4 MIR21 KRT20 CEACAM7 CEACAM5
41 serous cystadenocarcinoma 30.4 TYMP KRAS CDKN1A
42 suppression of tumorigenicity 12 30.4 MIR145 KRAS CEACAM5 CDKN1A
43 basal cell carcinoma 30.4 MSH2 MLH1 MIR143 KRT20 CEACAM5 CDKN1A
44 adenocarcinoma 30.3 TYMP MSH2 MMP7 MLH1 KRT20 KRAS
45 gallbladder disease 30.3 MIR17 MIR145 MIR143 KRAS CEACAM5
46 arteries, anomalies of 30.3 MIR21 MIR17 MIR145 MIR143
47 larynx cancer 30.3 MIR31 MIR21 MIR17 MIR143
48 ovarian serous carcinoma 30.3 MIR21 MIR20A MIR145 MIR143 KRAS
49 nasopharyngeal carcinoma 30.3 MIR31 MIR21 MIR17 MIR143 CDKN1A
50 bladder cancer 30.3 TYMS TYMP MLH1 MIR31 MIR21 MIR17

Graphical network of the top 20 diseases related to Rectum Cancer:



Diseases related to Rectum Cancer

Symptoms & Phenotypes for Rectum Cancer

MGI Mouse Phenotypes related to Rectum Cancer:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 9.17 APC CDKN1A KRAS MLH1 MMP7 MSH2

Drugs & Therapeutics for Rectum Cancer

Drugs for Rectum Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 560)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
2
Iron Approved, Experimental Phase 4 7439-89-6, 15438-31-0 23925 27284
3
Morphine Approved, Investigational Phase 4 57-27-2 5288826
4
Acetaminophen Approved Phase 4 103-90-2 1983
5
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
6
Hydromorphone Approved, Illicit Phase 4 466-99-9 5284570
7
Orphenadrine Approved Phase 4 83-98-7 4601
8
Hydrocodone Approved, Illicit, Investigational Phase 4 125-29-1 5284569
9
Methadone Approved Phase 4 76-99-3 4095
10
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
11
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
12
Ketorolac Approved Phase 4 66635-83-4, 74103-06-3 3826
13
Bevacizumab Approved, Investigational Phase 4 216974-75-3
14
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 5311068 68602
15
Udenafil Approved, Investigational Phase 4 268203-93-6 6918523
16
Sodium citrate Approved, Investigational Phase 4 68-04-2
17
Povidone-iodine Approved Phase 4 25655-41-8
18
Ertapenem Approved, Investigational Phase 4 153832-46-3 150610
19
Darbepoetin alfa Approved, Investigational Phase 4 11096-26-7, 209810-58-2
20
Ranibizumab Approved Phase 4 347396-82-1 459903
21
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
22
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
23
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
24
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
25
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
26
Pregabalin Approved, Investigational Phase 4 148553-50-8 5486971
27
tannic acid Approved Phase 4 1401-55-4
28
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
29
Zinc Approved, Investigational Phase 4 7440-66-6 32051
30
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
31
Tobramycin Approved, Investigational Phase 4 32986-56-4 36294 5496
32
Amphotericin B Approved, Investigational Phase 4 1397-89-3 14956 5280965
33
Colistin Approved Phase 4 1264-72-8, 1066-17-7 5311054
34
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
35 Antimanic Agents Phase 4
36 Anesthetics, Local Phase 4
37 Chlorpheniramine, phenylpropanolamine drug combination Phase 4
38 Antipyretics Phase 4
39 Neuromuscular Agents Phase 4
40 Respiratory System Agents Phase 4
41 Cytochrome P-450 Enzyme Inhibitors Phase 4
42 Anti-Arrhythmia Agents Phase 4
43 Excitatory Amino Acid Antagonists Phase 4
44 Excitatory Amino Acids Phase 4
45 Antiparkinson Agents Phase 4
46 Cholinergic Antagonists Phase 4
47 Muscarinic Antagonists Phase 4
48 Parasympatholytics Phase 4
49 Sodium Channel Blockers Phase 4
50 Diuretics, Potassium Sparing Phase 4

Interventional clinical trials:

(show top 50) (show all 1653)
# Name Status NCT ID Phase Drugs
1 Study of the Relationship Between the Rate of Residual Platinum in the Blood and the Incidence of Persistent Neurotoxicity in Patients Treated for Gastrointestinal Cancer With Oxaliplatin Unknown status NCT00274885 Phase 4 oxaliplatin
2 Randomized, Parallel Group, Clinical Trial Comparing Intravenous Iron Sucrose Versus Oral Ferrous Sulphate in the Treatment of Perioperative Iron Deficiency in Patients With Colo-Rectal Neoplasm and Iron Deficiency Anemia. Unknown status NCT00199277 Phase 4 i.v. iron sucrose;Oral iron
3 Multimodal Narcotic Limited Perioperative Pain Control With Colorectal Surgery as Part of an Enhanced Recovery After Surgery Protocol: A Randomized Prospective Single- Center Trial. Unknown status NCT02958566 Phase 4 Acetaminophen;Gabapentin;Orphenadrine;Lidocaine;Marcaine;Ketamine;Methadone;Tramadol;Ketorolac;Morphine Sulfate;Fentanyl;Dilaudid;Hydrocodone-Acetaminophen Tab 5-325 MG;Morphine Sulfate;Fentanyl;Dilaudid;HYDROCODONE/ACETAMINOPHEN 5 Mg-325 Mg ORAL TABLET
4 Multicentric, Prospective, Randomized and Simple Blind Study to Determine the Efficacy of the Placement of an Onlay Mesh for Prevention of Incisional Hernia After Loop Ileostomy Closure in Patients With a Prior Rectal Resection for Cancer Unknown status NCT02896686 Phase 4
5 Assessment of the Effect of Dexmedetomidine in the Management of Postoperative Pain When Combined With Fentanyl in the Patient-controlled Analgesia Completed NCT01373021 Phase 4 Fentanyl;Dexmedetomidine
6 The Efficacy of Penile Rehabilitation Using Udenafil After Total Mesorectal Excision of Rectal Cancer Completed NCT01421940 Phase 4 Placebo drug;Udenafil
7 A Non-randomised Controlled Trial of Early Intervention to Preserve Erectile Function After Laparoscopic Resection for Rectal Cancer Completed NCT01912586 Phase 4
8 Prospective Randomized Study of Single Incision Laparoscopic Surgery Versus Conventional Laparoscopic Surgery for Rectal Cancer Completed NCT01579721 Phase 4
9 Randomized, Controlled, Prospective Study of the Use of a Mesh to Prevent Parastomal Hernia After Laparoscopic Abdominoperineal Resection Completed NCT01722565 Phase 4
10 Phase 4 Study to Characterize and Evaluate Markers of Chemoresistance in Patients With Metastatic Colorectal Cancer Completed NCT00559676 Phase 4 capecitabine;fluorouracil;irinotecan hydrochloride;leucovorin calcium;oxaliplatin
11 Konzentrationen Von Ertapenem in Kolorektalem Gewebe Completed NCT00535652 Phase 4 Ertapenem
12 Compression Anastomosis: Initial Clinical Experience With the ColonRingTM Completed NCT01056913 Phase 4
13 The Effect of Darbepoetin Alfa Treatment Upon the Rehabilitation Following Planned Surgery for Colorectal Cancer Completed NCT00122720 Phase 4 Darbepoetin Alfa
14 Increasing CRC Screening in Health Plan Members Completed NCT00134589 Phase 4
15 A Randomized, Double-masked Study With Intraocular Anti-VEGF (Avastin®/Lucentis®) Compared With Intraocular Triamcinolone (Volon A®) in Patients With Clinical Significant Diabetic Macular Edema Completed NCT00682539 Phase 4 Bevacizumab (Avastin);Triamcinolone;Sham
16 Multi-Port vs. Single-port Cholecystectomy Completed NCT01104727 Phase 4
17 A Randomized, Open-label Study to Compare Propofol Anesthesia With Sevoflurane Anesthesia in Terms of Overall Survival in Patients With Surgical Intervention for Either Breast-, Colon- or Rectal Cancer Recruiting NCT01975064 Phase 4 Propofol;Sevoflurane
18 CT-guided Ganglion Impar Block for Management of Phantom Rectal Pain Syndrome Recruiting NCT03694639 Phase 4
19 Insulin Therapy Reduce Post-Operative Inflammatory Response After Curative Colorectal Cancer Resection: Randomization Controlled Trial Not yet recruiting NCT02746432 Phase 4 Hyper insulinemic euglycemic clamp
20 Transanal Endoscopic Microsurgery Versus Endoscopic Submucosal Dissection For Large Rectal Adenomas Suspended NCT01023984 Phase 4
21 An Open Label, Phase II Study of Capecitabine (Xeloda) Plus Conformal Radiotherapy for Patients With Locally Advanced, Non-Metastatic Rectosigmoid Carcinoma Terminated NCT00216424 Phase 4 Capecitabine (Xeloda)
22 Evaluating the Radial Reload Stapler With Tri-Staple TM Technology During Laparoscopic Low Anterior Resection for Rectal Cancer: A Prospective Multicenter Case Series Terminated NCT01706822 Phase 4
23 Perioperative Selective Decontamination of the Digestive Tract (SDD) in Elective Colorectal Cancer Patients: a Multicenter Randomized Clinical Trial Terminated NCT01740947 Phase 4 Selective decontamination of the digestive tract (SDD) (colistin sulfate, tobramycin, amphotericin B)
24 A Randomized Clinical Trial Comparing Laparoscopic and Open Surgery for Rectal Cancer. Unknown status NCT00297791 Phase 3
25 Preoperative Chemoradiation Versus Short Term Radiation Alone With Delayed Surgery for Stage II and III Resectable Rectal Cancer Unknown status NCT00597311 Phase 3
26 Prospective Randomized Clinical Trial for no Inferiority With Preoperative Chemoradiotherapy and Transanal Endoscopic Microsurgery (TEM) Versus Total Mesorectal Excision in T2-T3s N0, M0 Rectal Cancer Unknown status NCT01308190 Phase 3 Capecitabine (Xeloda)
27 The Randomised Study of Preoperative Radiotherapy and Local Excision for Radiosensitive Rectal Cancer Unknown status NCT00738790 Phase 3
28 5FU/VL Vs LV5FU2 + CPT11 in Stage II-III Resected Rectal Cancer Unknown status NCT00189657 Phase 3
29 Randomized Trial of Preoperative Radiotherapy With an Integrated Simultaneous Boost Compared to Chemoradiotherapy for T3-4 Rectal Cancer Unknown status NCT01224392 Phase 3
30 A Randomized Trial Comparing Concurrent Chemoradiation Versus Wide Pelvic Lymphadenectomy for Advanced Rectal Cancer Unknown status NCT00154752 Phase 3
31 Randomized Trial of Wide Mesorectal Excision Versus Total Mesorectal Excision for Mid Rectal Cancer Unknown status NCT00007930 Phase 3
32 An Open Label, Randomized, Multi-center, Phase II/III Trial of High Intensity Versus Low Intensity Neoadjuvant Chemoradiotherapy With Intensity-modified Radiation Therapy (IMRT) in Local Advanced Rectal Cancer Unknown status NCT01064999 Phase 2, Phase 3 Oxaliplatin;Capecitabine
33 RANDOMIZED TRIAL OF CONCOMITANT PREOPERATIVE RADIO-CHEMOTHERAPY WITH OR WITHOUT POSTOPERATIVE CHEMOTHERAPY IN LOCALLY ADVANCED RECTAL CARCINOMA Unknown status NCT00002896 Phase 3 chemotherapy;fluorouracil;leucovorin calcium
34 The Safety and Effect of Transanual Tube Placement in Low Anterior Resection (LAR) for Rectal Cancer to Prevent Anastomotic Leak: Randomized Control Trial Study Unknown status NCT02905968 Phase 2, Phase 3
35 A Clinical Trial Comparing Preoperative Radiation Therapy And Capecitabine With or Without Oxaliplatin With Preoperative Radiation Therapy And Continuous Intravenous Infusion Of 5-Fluorouracil With or Without Oxaliplatin In The Treatment Of Patients With Operable Carcinoma Of The Rectum Unknown status NCT00058474 Phase 3 capecitabine;fluorouracil;oxaliplatin
36 A Randomized Controlled Clinical Trial Comparing Oncological Results and Functional Recovery Between Laparoscopic and Open Method for the Treatment of Advanced Rectal Cancer After Concurrent Chemoradiation Therapy (CCRT) Unknown status NCT00601549 Phase 3
37 A Trial to Assess Robot-assisted Surgery and Laparoscopy-assisted Surgery in Patients With Mid or Low Rectal Cancer Unknown status NCT01423214 Phase 3
38 Long-term Results of Biological Mesh Closure of the Pelvic Floor After Extralevator Abdominoperineal Resection for Rectal Cancer Unknown status NCT01927497 Phase 3
39 Evaluation of Microdialysis to Monitor Postoperative Outcomes After Proctectomy Unknown status NCT01999634 Phase 3
40 Randomized Controlled Trial Comparing the Bladder and Sexual Functions of Patients Who Undergo Laparoscopic and Robotic Assisted Resection for Rectal Cancer Unknown status NCT01130233 Phase 3
41 Resource-Sparing Curative Treatment for Rectal Cancer Unknown status NCT01459328 Phase 3
42 Short-course Preoperative Radiotherapy With Consolidating Chemotherapy vs. Preoperative Chemoradiation in Patients With Unresectable Rectal Cancer: Phase III Study Unknown status NCT00833131 Phase 3
43 Mesh Reinforcement During Temporary Stoma Closure After Sphincter-Saving Rectal Cancer Surgery: A Randomized-controlled Trial Unknown status NCT02576184 Phase 3
44 Preoperative Hyperfractionated Radiotherapy Versus Combined Radiochemotherapy for Patients With Locally Advanced Rectal Cancer: a Phase III Randomized Trial. Unknown status NCT01814969 Phase 3
45 A Phase III, Randomized, Double-Blind Placebo Controlled Study of the Probiotic Preparation VSL#3® Versus Placebo in Increasing the Pathological Major Response Rate in Patients Receiving Concurrent Chemotherapy and Pelvic Radiation Therapy Unknown status NCT01579591 Phase 3
46 Anastomotic Leakage in Laparoscopic Anterior Resection With or Without "Dog Ear" Double-stapled Anastomosis for Rectal Cancer : A Prospective, Randomized, Controlled Study Unknown status NCT02770911 Phase 3
47 Randomized Phase III Trial Comparing in a Preoperative Schedule the Result of Two Concurrent Chemoradiation Schemes (45 Gy + Capecitabine vs 50 Gy + Capecitabine - Oxaliplatin) on the Rate of Sterilization of the Operative Specimen in Resectable Rectal Carcinomas T3-4 No-2 Mo Unknown status NCT00227747 Phase 3 capecitabine;oxaliplatin
48 A Comparison for Laparoscopically Assisted and Open Surgery for Advanced Rectal Cancer After Preoperative Chemoradiation- Randomized Prospective Trial Unknown status NCT00470951 Phase 3
49 INTEnsification Radiotherapy With Accelerated Fractionation or ChemoTherapy And Local Excision After 3D External Radio-chemotherapy Unknown status NCT01653301 Phase 3 XELAC RT;XELOX RT
50 Randomized Controlled Trial to Evaluate High Tie Versus Low Tie of the Inferior Mesenteric Artery in Rectal Anterior Resection for Rectal Cancer Patients Unknown status NCT01861678 Phase 3

Search NIH Clinical Center for Rectum Cancer

Cochrane evidence based reviews: rectal neoplasms

Genetic Tests for Rectum Cancer

Anatomical Context for Rectum Cancer

The Foundational Model of Anatomy Ontology organs/tissues related to Rectum Cancer:

19
Rectum

MalaCards organs/tissues related to Rectum Cancer:

40
Colon, Lymph Node, Liver, Lung, Testes, Breast, Prostate

Publications for Rectum Cancer

Articles related to Rectum Cancer:

(show top 50) (show all 22050)
# Title Authors PMID Year
1
Pharmacogenetic analysis in neoadjuvant chemoradiation for rectal cancer: high incidence of somatic mutations and their relation with response. 61 54
20504250 2010
2
Calcium, vitamin D, VDR genotypes, and epigenetic and genetic changes in rectal tumors. 61 54
20432164 2010
3
KRAS and BRAF mutations in patients with rectal cancer treated with preoperative chemoradiotherapy. 61 54
19913317 2010
4
Predictive factors of early relapse in UICC stage I-III colorectal cancer patients after curative resection. 61 54
19757443 2009
5
Microsatellite instability and survival in rectal cancer. 54 61
19669908 2009
6
Protein expression following gamma-irradiation relevant to growth arrest and apoptosis in colon cancer cells. 54 61
19504123 2009
7
Increased spontaneous apoptosis, but not survivin expression, is associated with histomorphologic response to neoadjuvant chemoradiation in rectal cancer. 61 54
19593573 2009
8
Experiences from treatment-predictive KRAS testing; high mutation frequency in rectal cancers from females and concurrent mutations in the same tumor. 61 54
19832985 2009
9
Prognostic value of postoperative CEA clearance in rectal cancer patients with high preoperative CEA levels. 61 54
19657698 2009
10
[Prognosis of rectal cancer patients after total mesorectal excision]. 61 54
19728904 2009
11
A simple scoring system based on clinical features to predict locally advanced rectal cancers. 54 61
19367434 2009
12
Carcinoembryonic antigen as a predictor of pathologic response and a prognostic factor in locally advanced rectal cancer patients treated with preoperative chemoradiotherapy and surgery. 54 61
19101093 2009
13
High Ki67, Bax, and thymidylate synthase expression well correlates with response to chemoradiation therapy in locally advanced rectal cancers: proposal of a logistic model for prediction. 61 54
19491899 2009
14
Topoisomerase I expression correlates to response to neoadjuvant irinotecan-based chemoradiation in rectal cancer. 54 61
19436196 2009
15
Dihydropyrimidine dehydrogenase mRNA expression in peripheral blood of rectal cancer patients is significantly associated with residual tumor and distant metastases following resection. 54 61
19180589 2009
16
Diagnostic precision of carcinoembryonic antigen in the detection of recurrence of colorectal cancer. 61 54
18619834 2009
17
Radiation-induced thymidine phosphorylase upregulation in rectal cancer is mediated by tumor-associated macrophages by monocyte chemoattractant protein-1 from cancer cells. 54 61
19215821 2009
18
Thymidylate synthase genotypes and tumour regression in stage II/III rectal cancer patients after neoadjuvant fluorouracil-based chemoradiation. 61 54
18722050 2008
19
Significance of thymidine phosphorylase expression in stromal cells around invasive front of rectal cancer. 61 54
19260474 2008
20
Survivin antisense oligonucleotides effectively radiosensitize colorectal cancer cells in both tissue culture and murine xenograft models. 54 61
18406888 2008
21
Importance of thymidine phosphorylase, dihydropyrimidine dehydrogenase and thymidylate synthase expression at the invasive front of T3 rectal cancer as prognostic factors. 54 61
18613375 2008
22
Predictive value of Ki67 and p53 in locally advanced rectal cancer: correlation with thymidylate synthase and histopathological tumor regression after neoadjuvant 5-FU-based chemoradiotherapy. 54 61
18286688 2008
23
Survivin, p53, and Ki-67 as predictors of histopathologic response in locally advanced rectal cancer treated with preoperative chemoradiotherapy. 54 61
17805549 2008
24
Biological predictive factors in rectal cancer treated with preoperative radiotherapy or radiochemotherapy. 54 61
18087284 2008
25
CDX2 VDR polymorphism and colorectal cancer. 54 61
18086783 2007
26
Germline mutations of the MYH gene in Korean patients with multiple colorectal adenomas. 54 61
17703316 2007
27
Carcinoembryonic antigen and patterns of recurrence after curative resection of the colorectal cancer. 61 54
18251140 2007
28
Dietary fat and risk of colon and rectal cancer with aberrant MLH1 expression, APC or KRAS genes. 61 54
17636402 2007
29
Prognostic and predictive value of baseline and posttreatment molecular marker expression in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy. 54 61
17445998 2007
30
Novel mutations and sequence variants in exons 3-9 of human T cell factor-4 gene in sporadic rectal cancer patients stratified by microsatellite instability. 54 61
17659738 2007
31
[Expression and clinical significance of matrilysin (MMP-7) in human rectal cancer]. 61 54
17718429 2007
32
Predictors of tumor response and downstaging in patients who receive preoperative chemoradiation for rectal cancer. 61 54
17387743 2007
33
[Fragile histidine triad protein expression and correlation with apoptosis in rectal carcinoma]. 61 54
17380463 2007
34
Clinicopathologic and prognostic significance of matrix metalloproteinases in rectal cancer. 54 61
16896992 2007
35
Colorectal cancer or colon and rectal cancer? Clinicopathological comparison between colonic and rectal carcinomas. 61 54
18334831 2007
36
Rectal cancer metastasis to the head of the pancreas treated with pancreaticoduodenectomy. 61 54
18040627 2007
37
[Quantification of PPARdelta mRNA by real-time RT-PCR in rectal cancer tissues]. 61 54
17294733 2007
38
A prospective, blinded analysis of thymidylate synthase and p53 expression as prognostic markers in the adjuvant treatment of colorectal cancer. 54 61
16971666 2006
39
[Influence and significance of preoperative intraarterial infusion chemotherapy combined with radiotherapy on survivin, p53 and Bax expression in low rectal carcinoma]. 61 54
17094914 2006
40
Gene expression levels of epidermal growth factor receptor, survivin, and vascular endothelial growth factor as molecular markers of lymph node involvement in patients with locally advanced rectal cancer. 54 61
17241515 2006
41
The impact of surgically induced ischaemia on protein levels in patients undergoing rectal cancer surgery. 54 61
17016487 2006
42
Predictors of recurrence in patients with T2 and early T3, N0 adenocarcinoma of the rectum treated by surgery alone. 61 54
16943525 2006
43
Prognostic value of histologic tumor regression, thymidylate synthase, thymidine phosphorylase, and dihydropyrimidine dehydrogenase in rectal cancer UICC Stage II/III after neoadjuvant chemoradiotherapy. 54 61
16931962 2006
44
Lymph node status and TS gene expression are prognostic markers in stage II/III rectal cancer after neoadjuvant fluorouracil-based chemoradiotherapy. 54 61
16943523 2006
45
Genetic dissection of apoptosis and cell cycle control in response of colorectal cancer treated with preoperative radiochemotherapy. 61 54
16686938 2006
46
Prognostic effect of perioperative change of serum carcinoembryonic antigen level: a useful tool for detection of systemic recurrence in rectal cancer. 54 61
16538413 2006
47
PPARgamma and colon and rectal cancer: associations with specific tumor mutations, aspirin, ibuprofen and insulin-related genes (United States). 61 54
16489531 2006
48
Anemia and long-term outcome in adjuvant and neoadjuvant radiochemotherapy of stage II and III rectal adenocarcinoma: the Freiburg experience (1989-2002). 54 61
16609990 2006
49
Quantitative analysis of PPARdelta mRNA by real-time RT-PCR in 86 rectal cancer tissues. 61 54
16361076 2006
50
Serum CEA as a predictor for the response to preoperative chemoradiation in rectal cancer. 61 54
16425302 2006

Variations for Rectum Cancer

Copy number variations for Rectum Cancer from CNVD:

7
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 139647 2 185171337 185512459 Copy number ZNF804A Rectal cancer
2 166960 3 1109627 1420278 Copy number CNTN6 Rectal cancer
3 225401 7 45400000 54000000 Copy number EGFR Rectal cancer

Expression for Rectum Cancer

Search GEO for disease gene expression data for Rectum Cancer.

Pathways for Rectum Cancer

GO Terms for Rectum Cancer

Cellular components related to Rectum Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mismatch repair complex GO:0032300 8.62 MSH2 MLH1

Biological processes related to Rectum Cancer according to GeneCards Suite gene sharing:

(show all 25)
# Name GO ID Score Top Affiliating Genes
1 cellular response to DNA damage stimulus GO:0006974 10.02 MUTYH MSH2 MLH1 CDKN1A APC
2 negative regulation of gene expression GO:0010629 9.92 MIR21 MIR20A MIR17 CDKN1A
3 positive regulation of angiogenesis GO:0045766 9.81 MIR31 MIR21 MIR20A MIR143
4 response to glucocorticoid GO:0051384 9.75 TYMS KRAS CDKN1A
5 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.73 MIR21 MIR20A MIR17
6 gene silencing by miRNA GO:0035195 9.63 MIR31 MIR21 MIR20A MIR17 MIR145 MIR143
7 positive regulation of cardiac muscle hypertrophy in response to stress GO:1903244 9.61 MIR20A MIR17
8 pyrimidine nucleoside catabolic process GO:0046135 9.61 TYMP DPYD
9 negative regulation of cardiac muscle cell apoptotic process GO:0010667 9.61 MIR21 MIR20A MIR145
10 positive regulation of isotype switching to IgG isotypes GO:0048304 9.6 MSH2 MLH1
11 positive regulation of metalloendopeptidase activity GO:1904685 9.59 MIR21 MIR17
12 angiotensin-activated signaling pathway GO:0038166 9.58 MIR145 MIR143
13 mismatch repair GO:0006298 9.58 MUTYH MSH2 MLH1
14 negative regulation of vascular associated smooth muscle cell apoptotic process GO:1905460 9.57 MIR21 MIR17
15 aorta smooth muscle tissue morphogenesis GO:0060414 9.55 MIR145 MIR143
16 positive regulation of isotype switching to IgA isotypes GO:0048298 9.54 MSH2 MLH1
17 positive regulation of vascular associated smooth muscle cell migration GO:1904754 9.54 MIR21 MIR20A MIR143
18 somatic recombination of immunoglobulin gene segments GO:0016447 9.52 MSH2 MLH1
19 regulation of phenotypic switching GO:1900239 9.49 MIR145 MIR143
20 intestinal epithelial cell maturation GO:0060574 9.48 TYMS CDKN1A
21 pyrimidine nucleobase metabolic process GO:0006206 9.46 TYMS TYMP
22 miRNA mediated inhibition of translation GO:0035278 9.35 MIR31 MIR21 MIR20A MIR17 MIR145
23 establishment or maintenance of cell type involved in phenotypic switching GO:0044663 9.32 MIR145 MIR143
24 somatic recombination of immunoglobulin genes involved in immune response GO:0002204 9.26 MSH2 MLH1
25 positive regulation of pulmonary blood vessel remodeling GO:1905111 8.8 MIR20A MIR17 MIR143

Molecular functions related to Rectum Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mismatched DNA binding GO:0030983 9.37 MSH2 MLH1
2 MutSalpha complex binding GO:0032407 9.32 MUTYH MLH1
3 MutLalpha complex binding GO:0032405 9.26 MUTYH MSH2
4 oxidized purine DNA binding GO:0032357 9.16 MUTYH MSH2
5 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.1 MIR31 MIR21 MIR20A MIR17 MIR145 MIR143
6 guanine/thymine mispair binding GO:0032137 8.96 MSH2 MLH1

Sources for Rectum Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....